ONCAlert | Upfront Therapy for mRCC
Videos  >  

Reviewing the Current Treatment Landscape for Patients With HCC

Ahmed Omar Kaseb, MD
Published Online:6:35 PM, Fri May 24, 2019

Ahmed Omar Kaseb, MD, associate professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the current treatment landscape for patients with hepatocellular carcinoma (HCC).

All systemic therapy is considered palliative only, Kaseb says. There are not any drugs approved in the neoadjuvant or adjuvant setting for patients with HCC, so many patients who are not surgical candidates suffer from a lack of effective adjuvant therapies to downsize their tumors.

In addition, those patients with HCC that do not make it to surgery suffer from a lack of effective drugs that could lower their recurrence rates.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.